Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes
Interventions: Basal insulin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Insulin Dependent
Interventions: Intensive Home-Based Family Therapy, Supportive Telephone Calls; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus
Interventions: CLBS03 Low Dose, CLBS03 High Dose, Placebo; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: 18F-AV-133; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: Islet Transplantation, Islet cell transplantation; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions: Imatinib Mesylate, Placebo (For imatinib mesylate); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Diabetes Mellitus, Type 1 Diabetes, Metabolic and Nutritional Disorders
Interventions: TTR controller (Medtronic); Device
Lead sponsor: Stanford University; Other
Eligibility: 15 Years to 30 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Celiac Disease
Interventions: Latiglutenase, Placebo; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Islet Transplantation, Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM); Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 25
States / cities: La Jolla, California • Palo Alto, California • Sacramento, California + 21 more

Conditions: Type1diabetes
Interventions: AHCL pump, Video conferencing Application; Device · Other
Lead sponsor: Children's Hospital New Orleans, LA; Other
Eligibility: 10 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Type1diabetes
Interventions: Regular insulin (Humulin-R), intranasal route, SipNose intranasal device; Drug · Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions: insulin aspart, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more

Conditions: Type1diabetes
Interventions: 4T Education and Care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 21 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type I Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions: Visbiome, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes Mellitus, Type 1, Diabetic Nephropathy
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 14 Years to 40 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Type 1 Diabetes Mellitus
Interventions: Islets of Langerhans transplantation; Biological
Lead sponsor: CellTrans Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Nephropathy
Interventions: Lisinopril, Nifedipine, Simvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Basic Education, Hypoglycemia Symptom Detection Training, Education Plus; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes
Interventions: Pump suspension; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 15 Years to 45 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus, Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

Medtronic Treat to Range (TTR) Closed-Loop Control

Triple Therapy in T1DM

Study of Latiglutenase in T1D/CD Patients

CGM Use in Islet Transplant Recipients

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

Accuracy of Blood Glucose Detection by Diabetes Alert Dogs

Probiotics in Newly Diagnosed T1D

Matrix Metalloproteinases and Diabetic Nephropathy

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise